Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “buy” rating restated by equities research analysts at Wells Fargo & Co in a report issued on Friday.

AMPH has been the subject of a number of other research reports. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 13th. Needham & Company LLC cut their price target on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 10th. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $23.00.

Shares of AMPH opened at $21.59 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.94 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $890.44 million, a PE ratio of 56.82, a P/E/G ratio of 8.77 and a beta of 1.38. Amphastar Pharmaceuticals has a 52-week low of $14.40 and a 52-week high of $21.65.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. The business had revenue of $75.54 million during the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The business’s revenue was up 30.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 EPS. On average, equities research analysts forecast that Amphastar Pharmaceuticals will post 0.1 EPS for the current fiscal year.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total transaction of $178,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 2,407 shares of the firm’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $17.59, for a total transaction of $42,339.13. Following the transaction, the chief financial officer now owns 86,836 shares of the company’s stock, valued at $1,527,445.24. The disclosure for this sale can be found here. Insiders sold a total of 28,502 shares of company stock valued at $558,373 in the last quarter. Insiders own 31.50% of the company’s stock.

Large investors have recently bought and sold shares of the business. Principal Financial Group Inc. lifted its stake in Amphastar Pharmaceuticals by 2.2% during the first quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after purchasing an additional 5,789 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in Amphastar Pharmaceuticals by 259.8% during the second quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock worth $160,000 after purchasing an additional 7,572 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals during the second quarter worth about $128,000. State of Wisconsin Investment Board lifted its stake in Amphastar Pharmaceuticals by 29.3% during the second quarter. State of Wisconsin Investment Board now owns 36,200 shares of the company’s stock worth $552,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Amphastar Pharmaceuticals by 4.9% during the second quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after purchasing an additional 3,193 shares during the last quarter. Hedge funds and other institutional investors own 42.86% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Read More: Stock Symbols and CUSIP Explained

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.